Gene therapy more cost effective than current treatments for hemophilia B
Deficient immune cells implicated in TB disease progression
4 June 2021UK regulator approves Pfizer jab for 12 to 15-year-olds
4 June 2021Gene therapy more cost effective than current treatments for hemophilia B
A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development.
